Shortlisted Abstracts for Oral Presentation
Watch these shortlisted Abstract Oral Presentation during Parallel Session 5A on Conference Day 2 - 20 July 2024 (Sat) 3.30pm - 4.30pm and vote for the Most Popular Oral Presentation by 20 July 2024 (Sat) 4.45pm
Augmented anti-tumour potency via functionalised mesenchymal stem cells for treatment of Peritoneal Carcinomatosis
by Dr Woo Jun Yung
Overexpression of a modified SerpinB9 molecule enhances allogeneic T cell persistence and tumor control by Granzyme B and Caspase inhibition
by Dr Lionel Low
A high-density microfluidic bioreactor for the automated manufacturing of CAR T cells
by Dr Sin Wei-Xiang
Single cell profiling by RNA sequencing and flow cytometry reveals distinct properties of Epstein-Barr Virus-Specific T cells (EBVSTs) armoured with Chimeric Antigen Receptors (CARs)
by Dr Lindsay Kua
Toward biomanufacturing of tissue membrane for tissue regenerative therapy
by Dr Le Quang Bach
CRISPR screen identifies Gene 14 for advancing allogeneic CAR-T therapy
by Ms Clara Koh Kai Ting
Shortlisted Abstracts for Poster Presentation
Watch these shortlisted Abstract Poster Presentation on Conference Day 1 - 19 July 2024 (Fri) 5.30pm - 6.30pm
Novel AOF cytokines and T cell culture media formulation development in human T cell expansion
by Mr Ho Chung Yin
Auto-imaging Cytometry On the Slide (ICOS) for quality control of CAR-T products
by Dr Jia Meng
Two forms of corneal endothelial cell replacement therapy in a non-human primate model of corneal endothelial dysfunction
by Ms Belinda Tan
Validation of human corneal endothelial cells harvested for SNECi therapy
by Ms Ng Xiao Yu
First-in-class modular ribozyme-based biosensor
by Ms Tan Chermaine
Innovative artificial antigen presenting cell (aAPC) design for optimized NK cell expansion and activation
by Ms Fariza
Accepted Poster Abstracts
Visit Room L1-S3 and discuss with Abstract Presenting Authors on their research during allocated breaks or throughout the conference.
You may vote for the Most Popular Abstract by 19 July 2024 (Fri) 6.30pm.
19 Jul (Fri) 12.00pm – 12.15pm
Novel AOF cytokines and T cell culture media formulation development in human T cell expansion
by Mr Ho Chung Yin
HO2 as a therapeutic biomarker: A promising new strategy for combatting metastatic non-small cell lung cancer
by Dr Seul-Ki Mun
Accelerated CD19 CAR T-Cell manufacturing with enhanced vector transduction and reduced risk of CRS
by Dr Fazil Turabe
Advancing regenerative medicine: Human Trophoblast Stem Cells from Ectopic Tissue
by Mr Henry Chen
Two forms of corneal endothelial cell replacement therapy in a non-human primate model of corneal endothelial dysfunction
by Ms Belinda Tan
Analysing genetic variants and trinucleotide repeats in an asian multi-ethnic Fuchs endothelial corneal dystrophy cohort
by Ms Neo Jing Hui Dawn
STEM-T reprogramming platform technology to empower adoptive immunotherapy for solid tumor
by Dr Ong Li Teng
Optimizing the expansion and transduction of gd T cells from cord blood
by Ms Lim Pei Yu
First-in-class modular ribozyme-based biosensor
by Ms Chermaine Tan
Preclinical efficacy and safety of nebulized mesenchymal stem cells-derived extracellular vesicles in sub-health volunteers
by Mr Raymond Lv Pinlei
Mesenchymal stem cell therapy for Sjogren’s Syndrome: A systematic review of clinical trials
by Dr Faisal Parlindungan
Exploiting biophysical markers of CD8+ T Cell senescence to enhance CAR-T cell therapy
by Ms Jessalyn Low Hui Ying
19 Jul (Fri) 12.15pm – 12.30pm
Overcoming challenges in manufacturing of allogeneic natural killer (NK) cell therapies: What have we accomplished?
by Dr Wang Qiuxia, Chelsia
LCK knockout CAR-T Cells as a novel allogeneic platform
by Ms Previtha Dawn Sakthi Vale
PhytoChol®, a plant derived cholesterol as a direct replacement for transitioning to chemically-defined media
by Ms Kavitha Rajasekhar
End-to-end manufacturing of autologous CAR T cell therapies with the new Sefia™ cell therapy manufacturing platform
by Dr Chong Da Tan
Differentiation of hemogenic endothelia, CD34+ cells and macrophages from hiPSCs and hESCs
by Ms Lim Yee Ching
Cost-effectiveness and budget impact analyses of Axicabtagene Ciloleucel as second-line therapy in patients with large B-cell lymphoma in Singapore
by A/Prof Francesca Lim Wei Inng
A therapeutic approach targeting Twist1-p21 axis in MDA-MB-231, well-known Triple-negative breast cancer cells
by Ms Haelim Yoon
Transcriptomic signatures and functional characteristics of mesenchymal stromal cells in the MDS/MPN overlap syndromes
by Asst. Prof Than Hein
Semi-automated system for biomanufacturing of large hydrogel scaffold
by Mr Chan Weng Wan
19 Jul (Fri) 4.00pm – 4.15pm
Auto-imaging Cytometry On the Slide (ICOS) for quality control of CAR-T products
by Dr Jia Meng
Discovery of unshared TCRs recognizing LMP-derived epitopes from EBV variants
by Ms Andrea Budiman
Human iPSC-derived lung organoids as disease model to explore paracrine crosstalk in the tumour microenvironment associated with EGFR-TKI resistant NSCLC
by Ms Nalini Devi Verusingam
Non-viral, high-throughput primary immune cell transfection using high aspect-ratio nanostraws
by Mr Arun Kumar Ravi Kalaiselvi
Validation of human corneal endothelial cells harvested for SNECi therapy
by Ms Ng Xiao Yu
In-vivo base editing targeting human haematopoietic stem cells in a patient-derived humanised mouse of β-Thalassaemia Major
by Ms Nur Nazneen Yusof
A comparative study of CS10 and in-house freezing media for the cryopreservation of isolated CD34+ cells
by Ms Samantha Lim Pei Si
Feasibility of wash and formulation of mesenchymal stem cells in low-volume for intra-tumoral delivery using closed counterflow centrifugation
by Dr Soong Poh Loong
Innovative artificial antigen presenting cell (aAPC) design for optimized NK cell expansion and activation
by Ms Fariza
Mesenchymal Stem Cells protection mechanisms against glutamate-induced neuronal cell apoptosis
by Mrs Firda Asma'ul Husna
Utilizing Mesenchymal Stem Cell-Derived extracellular vesicles for cancer cytotoxicity through modulation of cancer stem cell signaling pathways
by Ms Milya Urfa Ahmad
Scalable solutions for expansion of non-virally generated CAR T cells
by Ms Trang Nguyen
19 Jul (Fri) 4.15pm – 4.30pm
Sonogenetic control of multiplexed genome regulation and base editing
by Dr Liu Pei
Cultivated corneal stromal keratocytes produce functional proteoglycans to restore corneal clarity
by Asst. Prof Andri K. Riau
Anti-ageing effect of human umbilical cord-derived mesenchymal stromal cells conditioned medium on senescent normal human dermal fibroblast
by Ms Lee Soke Sun
Producing genetically-corrected haemopoietic stem cells from Beta-Thalassemia patients’ induced pluripotent stem cells: An alternative strategy for ex-vivo gene modification
by Ms Janani Ramesh
An investigation using maternal stem cells in a non-human primate model: Intrauterine transplantation and post natal boost
by Ms Julie Su Li Yeo
BECA: Development-to-manufacturing platform for immune cell therapies
by Dr Chen Sixun
Targeting NLRP3 inflammasome and SIRT3 pathways: A potential strategy for enhancing stem cell survival in Ischemic Stroke
by Prof Syed Shadab Raza
Comparison of the immunomodulatory capability of Mesenchymal Stem Cells from umbilical cord with those from adipose tissue
by Dr Isabella Kurnia Liem
Non-viral genome editing in Hematopoietic Stem Cells (HSCs) for cell-therapy applications - From discovery to manufacturing
by Dr Soong Poh Loong
SELECTION PROCESS
The Scientific Committee will evaluate all submissions and shortlist the posters for abstract poster presentation and oral presentation for each category.
Applicants will need to complete the submission form below and submit it.
The shortlisted applicants will be notified on the outcome of abstract poster and oral presentation by 14 JUNE 2024.
ELIGIBILITY
All are welcome to submit abstracts related to cell and gene therapy research. All abstract authors have an opportunity to be considered for abstract awards, as applicable.
Abstract submissions are free and should be submitted before the submission deadline: 10 JUNE 2024 (Extended).
ABSTRACT SUBMISSION FORM
-
All applicants are required to submit the online abstract form.
-
Please note that this is a one-time submission and all information should be readily available before you proceed with the online submission. For any amendments after submission, please send in to [email protected] latest by 31 MAY 2024.
-
All submission must be in English.
-
Abstract’s title should be concise and indicative of the content of the abstract.
-
Details of authors should be given in accordance to descending order of contribution (from most to least).
-
Abstracts should not exceed 300 words. For the result section, it is not satisfactory to state, “The result will be discussed”.
-
The use of standard abbreviations is desirable. Place special or unusual abbreviations in brackets after the full word the first time it appears. Use numerals to indicate numbers, except to begin sentences.
-
Please ensure the submitted abstract form and poster does not contain spelling, grammatical or scientific errors. Posters will be reproduced exactly as submitted, and no proof reading will be undertaken.
-
The use of tables, graphs and other types of images is not permitted in the online abstract submission form but permitted in poster.
-
Abstracts not adhering to the above will not be considered. Abstracts' authors will need to register as a delegate and are encouraged attend all the sessions in the conference.
-
Abstracts' authors will need to register as a delegate and are encouraged to attend all the sessions in the summit.
ABSTRACT CATEGORIES
CATEGORY 1: BASIC SCIENCE & TRANSLATIONAL RESEARCH
Includes research in the areas of science that is considered fundamental to the study and practice of medicine for e.g. anatomy, physiology, pathology, epidemiology, biochemistry etc. as well as translational research, which aims to facilitate the application of basic scientific discoveries in clinical and community settings.
Includes research that is conducted with human subjects or on material of human origin such as tissues, specimens and cognitive phenomena for which an investigator (or a colleague) directly interacts with human subjects.
Includes case study or research not limited to improvements in cell therapy patient experience, patient safety, clinical outcomes or transformative practices.
CATEGORY 2: CLINICAL RESEARCH
CATEGORY 3: NURSING & ALLIED HEALTH
ABSTRACT AWARDS
1. Most Popular Abstract Poster*
2. Most Popular Oral Presentation**
3. Best Abstract Poster and Oral Presentation for each category
*All posters will be displayed at the conference venue and voting by public will take place on 19 July 2024 .
**Voting by public will take place at the conference directly after the last oral presentation on 20 July 2024.
For Best Abstract Poster and Oral Presentation for each category, it will be evaluated for scientific merit by the Scientific Committee.
The award recipients will be announced during the Award Presentation Ceremony on 20 July 2024.
IMPORTANT DATES
Abstract submission closing date
10 JUNE 2024
Shortlisted applicants notified on the outcome of abstract poster and oral presentation
14 JUNE 2024
Public Voting for Poster Presentation
19 JULY 2024
Public Voting for Oral Presentation
20 JULY 2024
Announcement of All Award Winners
20 JULY 2024
PRESENTING AUTHOR'S PARTICULARS
Salutation*
Department*
Mailing Address*
Postal Code*
Contact Number*
Full Name*
Institution*
City & State / Province*
Country*
Email*
ABSTRACT INFORMATION
Abstract Category*
Authors must select one category that best fit their abstracts. The Scientific Committee reserves the right to re-categorise an abstract.
Abstract Title*
Preferred Mode of Presentation*
Authors must select the preferred mode of presentation for their abstracts. The Scientific Committee reserves the right to change the mode of presentation.
Abstract Content*
Text length NOT to exceed 300 words. The text of the abstract should include section headings such as Background/Aim, Methods, Results and Conclusion. The section headings should appear in bold.
Word Count: 0
CO-AUTHOR(S)' INFORMATION
There is no co-author for this abstract.
Full Name*
Department*
City & State / Province*
Email*
Institution of Affiliation*
Country*
There is no co-author for this abstract.
Powered by
